To gain some perspective, analysts have predicted sales of Venetoclax of US$2B by 2020 - approval was granted in April 2016. As previously discussed, Venetoclax works by blocking the pro-survival protein Bcl-2. The efficacy of Venetoclax, however, is apparently dependent upon the expression profile of Bcl-2, Bcl-x and Mcl-1. Sensitivity to Venetoclax is correlated with high Bcl-2 and low Bcl-x and Mcl-1.
Phylogica's presentation in January 2017 refers to FPP-Bim and the synergistic targeting of Myc and pro-survival proteins. We understand from the presentation that FPP-Bim targets all pro-survival proteins.
Does this resolve the problem around the expression profile of Bcl-2, Bcl-x and Mcl-1? Could FPP-Bim potentially have universal application regardless of the expression profile of the Bcl-2 family of proteins?
The project, Dual targeting of Myc and apoptosis pathways for improved blood cancer treatment outcomes, may provide answers. The project could deliver at multiple levels for shareholders in Phylogica.
PYC Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)